Summary
This report aims to analyze the current and future potential of prostate cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. This report is written for you to identify your competition and understand which targeting strategies are at work within prostate cancer drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you. Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the prostate cancer field and identified 135 drug targets belonging to 193 drugs. This report, Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs. In the report, BioSeeker reports on 116 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 193 prostate cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development. To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of prostate drugs. No less than 300+ target-target interactions were recognized among and between 110 of the 135 included prostate cancer drug targets. Why You Should Own Your Own Copy of this Report: - 300+ pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
- A 193 prostate cancer drugs analysis, under development by 135 investigators
- 135 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other prostate cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of prostate cancer drugs into R&D approaches
- Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
- Pathway profiling of prostate cancer drug targets
- Compound strategies based on sub-cellular localization of drug targets
- Expression levels of identified drug targets in prostate cancer tissue
- Structure based drug design in prostate cancer
- Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no competition
In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.
|
